Skip to main content

PAPEL DE LA INMUNIDAD INNATA Y LA SENESCENCIA DE LA MICROGLIA EN LAS ALTERACIONES ESTRUCTURALES Y FUNCIONALES ASOCIADAS A LA NEURODEGENERACION EN LA RETINOSIS PIGMENTARIA

PID2022-138917OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Polarised human alveolar epithelia enable identification of dichloroacetate as an effective drug against respiratory viruses

  • Martínez de Iturrate, Paula
  • Hernáez, Bruno
  • De los Santos, Patricia
  • García-Gómez, Alba
  • Sánchez-Cruz, Alonso
  • Hernández-Sánchez, Catalina
  • Rivas, Luis
  • Val, Margarita del
  • Rial, Eduardo
24 p.-6 fig., Respiratory viral infections are a significant cause of morbidity and mortality worldwide. The COVID-19 pandemic has highlighted the lack of chemotherapeutic tools available for fighting emerging viruses and the need to focus on preclinical models that better recapitulate human disease. We performed a comparative analysis of inhibitors of the PI3K/AKT/mTOR pathway, which is involved in virus-induced metabolic reprogramming, since strategies aimed at identifying cellular targets could serve to combat diverse viruses and hamper the development of resistance. Tests were performed in two human cell lines, MRC5 lung fibroblasts and Huh7 hepatoma cells, and the results showed that the inhibitors had markedly different effects on energy metabolism and antiviral activity. Thus, dichloroacetate (DCA) has potent antiviral activity against HCoV-229E in MRC5 cells but not in Huh7 cells, suggesting that the screening model is more critical than previously assumed. DCA was then tested in polarized human alveolar epithelia in air-liquid interface, a 3D model used to study respiratory infections. DCA reduced the viral progeny of HCoV-229E, SARS-CoV-2 and respiratory syncytial virus by 2-3 orders of magnitude, and it was effective even when applied once infection had been established. Although DCA has previously been shown to be effective against other viruses, suggesting that it could be a broad-spectrum antiviral, our experiments reinforce the need to use physiologically appropriate disease models to screen antiviral compound., This research work was funded by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global, SGL2103051); the Spanish National Research Council (CSIC) grants CSIC-COV19-110 and 202020E254; and the MICIU/AEI/10.13039/501100011033 / FEDER under grants PID2019-108166GB-I00 (to LR) and PID2022- 138917OB-I00 (to CHS)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Human Small Airway Epithelia Reveal Dichloroacetate as a Broad-Spectrum Antiviral Against Respiratory Viruses

  • Martínez de Iturrate, Paula
  • Hernáez, Bruno
  • Santos, Patricia de los
  • Sierra-Palomares, Yolanda
  • García-Gómez, Alba
  • Sánchez-Cruz, Alonso
  • Hernández-Sánchez, Catalina
  • Rivas, Luis
  • Val, Margarita del
  • Rial, Eduardo
Respiratory viral infections are a major cause of morbidity and mortality worldwide. The COVID-19 pandemic has evidenced the need for broad-spectrum antivirals and improved preclinical models that more accurately recapitulate human respiratory disease. These new strategies should also involve the search for drug targets in the infected cell that hamper the development of resistance and of potential efficacy against diverse viruses. Since many viruses reprogram cellular metabolism to support viral replication, we performed a comparative analysis of inhibitors targeting the PI3K/AKT/mTOR pathway, central to virus-induced metabolic adaptations, using MRC5 lung fibroblasts and Huh7 hepatoma cells. HCoV-229E infection in MRC5 cells caused the expected shift in the energy metabolism but the inhibitors had markedly different effects on the metabolic profile and antiviral activity in these two cell lines. Dichloroacetate (DCA), a clinically approved inhibitor of aerobic glycolysis, showed antiviral activity against HCoV-229E in MRC5 cells, but not in Huh7 cells, underscoring that the screening model is more critical than previously assumed. We further tested DCA in polarized human small airway epithelial cells cultured in air–liquid interface, a 3D model that mimics the human respiratory tract. DCA reduced the viral progeny of HCoV-229E, SARS-CoV-2, and respiratory syncytial virus by 2–3 orders of magnitude, even when administered after infection was established. Our work reinforces the need for advanced human preclinical screening models to identify antivirals that target host metabolic pathways frequently hijacked by respiratory viruses, and establishes DCA as a proof-of-concept candidate., This research was funded by the European Commission—NextGenerationEU (Regulation EU 2020/2094) through the CSIC’s Global Health Platform (PTI Salud Global, SGL2103051); the Spanish National Research Council (CSIC) grants CSIC-COV19-110 and 202020E254 and the Talent Attraction Program Grant (20222AT010) to support Y.S.-P.; and the MICIU/AEI/10.13039/501100011033/FEDER under grants PID2019-108166GB-I00 (to L.R.) and PID2022-138917OB-I00 (to C.H.-S.). P.d.l.S. was supported by a Garantía Juvenil contract of the Comunidad de Madrid (PEJ-2020-TL/BMD-18670)., Peer reviewed